NOVOLOG MIX 50/50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NOVOLOG MIX 50/50 (NOVOLOG MIX 50/50).
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
| Metabolism | Primarily metabolized by enzymatic cleavage via insulin-degrading enzyme (IDE) in the liver and kidneys. |
| Excretion | Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%). |
| Half-life | 6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes). |
| Protein binding | ~55% (primarily to albumin; also to insulin-specific antibodies if present). |
| Volume of Distribution | 0.4-0.6 L/kg (reflects distribution into extracellular fluid and tissues). |
| Bioavailability | Subcutaneous: 60-80% (variable due to degradation at injection site and individual factors). |
| Onset of Action | Subcutaneous: 10-20 minutes. |
| Duration of Action | Subcutaneous: 12-16 hours (due to biphasic mixture of rapid- and intermediate-acting insulin). |
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines for renal impairment. Due to potential for prolonged insulin action, monitor blood glucose closely and adjust dose as needed. Consider dose reduction in severe renal impairment. |
| Liver impairment | No specific dose adjustment guidelines for hepatic impairment. Hepatic impairment may affect glucose metabolism; monitor blood glucose closely and adjust dose as needed. Dose reduction may be necessary in severe hepatic dysfunction. |
| Pediatric use | Safety and efficacy in pediatric patients not established by clinical studies. Use with caution; dosing should be individualized based on age, weight, and blood glucose monitoring. |
| Geriatric use | Elderly patients may have reduced renal function and higher risk of hypoglycemia. Initiate with lower doses (e.g., 0.2-0.5 unit/kg/day) and titrate slowly based on blood glucose response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NOVOLOG MIX 50/50 (NOVOLOG MIX 50/50).
| Breastfeeding | Insulin aspart is a large protein molecule that is unlikely to pass into breast milk in significant amounts. The M/P ratio has not been established. Insulin aspart is considered compatible with breastfeeding, but caution is advised; monitor infant for signs of hypoglycemia. |
| Teratogenic Risk | Insulin aspart (NovoLog Mix 50/50) does not cross the placenta in significant amounts; therefore, teratogenic risk is low. Poor glycemic control during the first trimester is associated with increased risk of congenital anomalies. During the second and third trimesters, maternal hyperglycemia increases risk of macrosomia, polyhydramnios, and neonatal hypoglycemia. Insulin requirements typically increase in the second and third trimesters due to insulin resistance. |
■ FDA Black Box Warning
No specific FDA black box warning. However, insulin therapy carries a risk of severe hypoglycemia.
| Serious Effects |
["Hypersensitivity to insulin aspart or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse effect; dose adjustments required with changes in physical activity or meal patterns.","Never share pens or needles due to risk of blood-borne pathogens.","Monitor glucose closely in patients with renal or hepatic impairment.","May cause hypokalemia; caution in patients on potassium-lowering drugs or sensitive to potassium concentrations."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently, especially during dose titration. Perform HbA1c every 1-2 months. Assess for hypoglycemic episodes. Monitor fetal growth via ultrasound to detect macrosomia or intrauterine growth restriction. Fetal monitoring for diabetic mothers per guidelines. |
| Fertility Effects | No known adverse effects on fertility. Improved glycemic control may improve fertility in women with diabetes. |